alexa Osteoporosis and its association with non-gonadal hormones involved in hypertension, adiposity and hyperglycaemia.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Obesity & Weight Loss Therapy

Author(s): Poudyal H, Brown L

Abstract Share this page

Abstract Osteoporosis is a high-prevalence disease, particularly in developed countries, and results in high costs both to the individual and to society through associated fragility fractures. There is an urgent need for identification of novel drug targets and development of new anti-osteoporotic agents. Between 30 and 80\% of osteoporotic fractures cannot be prevented despite current treatments achieving relative fracture risk reduction of up to 20\%, 50\%, and 70\% for non-vertebral, hip and spine fractures, respectively. Traditionally, the decline in gonadal hormones has been studied as the sole hormonal determinant for the loss of bone mineral density in osteoporosis. However, recent studies have identified receptors for numerous non-gonadal hormones such as PTH, angiotensin II, leptin, adiponectin, insulin and insulin-like growth factor-1 on the osteoblast lineage cells that directly regulate bone turnover. These hormones are also involved in the pathogenesis of metabolic syndrome risk factors, particularly hypertension, type-II diabetes and obesity. By activating their respective receptors on osteoblastic lineage cells, these hormones appear to act through a common mechanism by down-regulating receptors for activation of nuclear factor kappa B ligand (RANKL) and up-regulating osteoprotegerin (OPG) with inverse responses for adiponectin. Receptors for amylin, gastric inhibitory polypeptide and ghrelin and have also been identified on the osteoblast lineage cells although the roles of these receptors in bone turnover are controversial or poorly studied. Moreover, bone turnover may be independently regulated by modulation of osteoclast-osteoblast function and bone marrow adiposity. Leptin appears to be the only hormone that is a known regulator of both bone mineralisation and bone adiposity.
This article was published in Curr Drug Targets and referenced in Journal of Obesity & Weight Loss Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 13th World Congress on Obesity
    Aug 24-25, 2017, Toronto, Canada
  • 13th Euro Obesity and Endocrinology Congress
    Sep 21-23, 2017, Madrid, Spain

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords